SS-31 (Elamipretide)
Cardiolipin biology and mitochondrial energy production.
Research Summary
- Evidence
- Human evidence is indication-specific
- Primary research
- Elamipretide clinical trials, including the Barth syndrome programme.
- Research focus
- Cardiolipin biology and mitochondrial energy production.
- Mechanism
- Elamipretide interacts with cardiolipin at the inner mitochondrial membrane.
- Evidence limits
- Evidence in Barth syndrome does not validate general anti-aging or a universal mitochondrial-repair sequence.
What SS-31 is
SS-31 is the research name for a drug called elamipretide, also known as Bendavia or MTP-131. Cells contain mitochondria, the parts that turn food into usable energy. SS-31 binds to cardiolipin, a fat that helps hold the inner wall of the mitochondria in the right shape. The drug has a real FDA approval, sold under the name Forzinity, for improving muscle strength in people with Barth syndrome who weigh at least 30 kg. It has also produced measurable changes in how much energy human cells can make [1-6].
The story often seen online is that your mitochondria are damaged, SS-31 repairs them, and only then can NAD+ or MOTS-c work properly. Parts of that story come from real biology, but the full sequence has never been shown to happen in a human study.
The most important point. Being tired, having brain fog, getting older, or feeling better or worse after taking SS-31 does not tell you whether your mitochondria were broken. How you react to SS-31 is not a test for mitochondrial damage.
Is SS-31 FDA approved?
Yes, for one rare disease only. The approval does not cover general “mitochondrial repair.” On 19 September 2025, the FDA approved Forzinity (elamipretide) to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. Barth syndrome is a rare inherited disease in which faulty cardiolipin biology is the central problem [1,2,15].
- Approved use: improving muscle strength in Barth syndrome, in people weighing 30 kg or more [1,2].
- Approved dose: 40 mg injected under the skin once a day in that specific group. Some adults with reduced kidney function get a lower dose [1].
How it was approved
- A small randomised trial. Twelve people, with the drug compared against placebo [2,4].
- Both original goals missed. Walking distance over six minutes and tiredness were no better than placebo [2,4].
- Muscle strength improved. Knee strength rose in the longer phase where everyone knew they were on the drug [2,3].
- Approved conditionally. The FDA accepted strength as a stand-in likely to predict benefit under accelerated approval. A confirmatory trial is still required [15,19].
The approval shows that elamipretide is a real medicine with real evidence behind it, covering one specific mitochondrial disease and one specific outcome. It does not prove that healthy people have damaged mitochondria, that SS-31 permanently repairs them, or that it reliably gives ordinary users more energy. The FDA calls Forzinity a mitochondrial cardiolipin binder, and the approved claim is improved muscle strength in Barth syndrome rather than “repairs mitochondria” [1,2].
Dosing evidence
SS-31 dosing gets confusing because three different things keep getting blended together: doses used in human trials, doses circulating on peptide sites, and rules invented around the “mitochondrial repair” story. Pharmacology can settle some of these questions but not all of them.
What humans were given in trials
| Study | Dose and route | Notes |
|---|---|---|
| Early muscle-disease dose study | 0.01, 0.10 or 0.25 mg/kg/hour by IV over 2 hours, once a day for 5 days | An IV research design, not a home injection protocol [7]. |
| Older adults with measurably low energy output | 0.25 mg/kg/hour by IV over 2 hours, once | Cell energy output improved right away; fatigue resistance did not. An IV dose cannot simply be converted milligram-for-milligram into an under-the-skin dose [6]. |
| Heart failure trial | 4 mg or 40 mg SC once daily for 28 days | A genuine low-dose human anchor for injection, but neither dose proved a general energy benefit and the main heart measure did not improve [10]. |
| Muscle-disease and Barth programmes | 40 mg SC once daily | Used across MMPOWER-2, MMPOWER-3 and the Barth trials. It is now the approved Forzinity dose for Barth syndrome at 30 kg and above, and it is not a general wellness dose [1,4,8,9]. |
Every dose on one scale
| Daily amount | Source | Status |
|---|---|---|
| 4 mg | Tested under the skin in a human trial | Tested in humans by injection |
| 40 mg | Approved dose for Barth syndrome | Tested in humans by injection |
| 0.5 to 1 mg | Community low-dose start | Community amount, not established in trials |
| About 5 mg | Most repeated community amount | Community amount, not established in trials |
| 10 to 20 mg | Pushed by some community pages | Community amount, not established in trials |
No amount between 4 mg and 40 mg has been studied by injection in any human trial.
What community protocols describe
Peptide sites do not agree on a single standard. Across community pages, the broad cluster is roughly 0.5 to 10 mg under the skin once a day. The single most repeated “working” amount is around 5 mg a day. 0.5 to 1 mg shows up as a cautious starting approach, while some pages push 10 to 20 mg a day. Some guides describe 500 mcg daily at first, then 1 to 2 mg a day. The popular 5-days-on / 2-days-off pattern and the 4 to 8 week “repair cycle” are community inventions and were not taken from any trial. None of these community protocols has been validated.
What the pharmacology can and cannot settle
| Question | Status | What the evidence shows |
|---|---|---|
| Dose frequency | Settled | Once a day, every day, makes more pharmacological sense than 5 on / 2 off. FDA data show the drug is absorbed quickly (peak blood level about 30 to 60 minutes after injection), that about 92% of an injected dose reaches the bloodstream, that doubling the dose roughly doubles the blood level across 2 to 80 mg, and that it barely builds up day to day. The approved label and every major injection trial use daily dosing. There is no receptor to “reset” and no weekend-repair rationale [1,4,8-10]. |
| Timing | Settled | Consistency matters more than timing around workouts. The label says the same time each day. No human trial shows that fasting, morning dosing or injecting 30 to 60 minutes before exercise improves anything [1]. |
| Cycling | Settled | No scheduled break or step-up ladder has been established. If the goal is less exposure, lowering the daily amount is more internally consistent than inventing two untested days off. Feeling tired is not a reason to push the dose because “repair is happening,” and feeling nothing is not evidence that a higher dose is needed. |
| The four-week mark | Settled | Treating four weeks as a point to reassess is more defensible than calling 4 to 8 weeks a “repair cycle.” Several human injection studies assessed at four weeks, so it is a real research window. It does not mean mitochondria are “repaired” by week 4. Longer stretches of 12 to 24 weeks and beyond have also been studied in people with disease [4,8-10]. |
| How much | Not settled | Only two under-the-skin doses have been given to humans in a trial: 4 mg and 40 mg. Both were tested in trials that missed their primary endpoints, and nothing between them has been studied. The 40 mg figure is the approved dose for one rare disease, and 4 mg shows only that a low dose was tolerated [1,9,10]. |
Logic can rule things out: daily dosing beats 5-on/2-off, pre-workout timing has no basis, and a “repair cycle” is not a milestone anyone has measured. Logic cannot produce an amount. The human data do not establish a benefit in healthy people at any dose, so there is no effect to dose toward and no non-arbitrary number to land on. Averaging a failed trial's low arm against the most repeated figure on vendor sites produces a number that only looks triangulated.
Human trial evidence
Mitochondria are involved in a lot of diseases, so elamipretide has been tested in very different groups of people. The results are not uniformly good. A convincing mechanism does not guarantee that a drug helps everywhere it is tried [4-12].
| Population | Result | What was found |
|---|---|---|
| Older adults with measurably underperforming mitochondria | Positive signal | A single IV dose. The amount of energy their cells could make went up right away, but their resistance to fatigue did not meaningfully improve [6]. |
| Inherited mitochondrial muscle disease (MMPOWER-2) | Encouraging but small | 40 mg under the skin daily for 4 weeks in 30 people. People walked about 20 m further in six minutes, small enough that it could have been chance. The fatigue questionnaires moved more clearly, though those were secondary measures and the larger trial that followed did not reproduce them [8,9]. |
| Inherited mitochondrial muscle disease (MMPOWER-3) | Main result negative | 40 mg under the skin daily for 24 weeks, 218 people with genetically confirmed mitochondrial disease. No better than placebo for walking distance or overall tiredness; both groups improved by almost exactly the same amount. In a subgroup planned before the trial began, people whose disease came from faults in nuclear DNA walked further, while those whose disease came from faults in mitochondrial DNA showed no difference. That is a real signal worth studying further, and it is a subgroup result inside a trial that failed overall [9]. |
| Barth syndrome | Narrow positive | 40 mg under the skin daily. Approved for muscle strength, but the original walking and tiredness measures were negative [1,2,4,5]. |
| Heart failure with a weakened pump | Main result negative | 4 mg or 40 mg under the skin daily for 28 days in 71 people. No meaningful improvement in the main measurements of heart size and pumping [10]. |
| Major heart attack | Main result negative | Given by IV during the procedure to reopen the blocked artery. It did not reduce the amount of damaged heart muscle or improve the other planned outcomes [11]. |
| Narrowed kidney artery | Preliminary only | A small IV pilot around a stent procedure. Blood flow and oxygen measures in the kidney looked better, but 14 people is not proof of kidney repair [12]. |
SS-31 has a real target and real effects in humans. Whether those effects turn into a benefit depends on the disease, on what is going wrong inside it, and on what the trial chose to measure. A mechanism that works in one setting can fail completely in another.
Is the energy effect real, or placebo?
SS-31 has measurable biological effects. The harder question is whether it reliably makes people feel more energetic, and human trials give a mixed answer [6,8,9].
| Group | Rise in cell energy output straight after a single IV dose |
|---|---|
| Elamipretide | +27% from baseline |
| Placebo | +12% from baseline |
This was in 39 selected older adults, with complete data for 18 per group. The result was borderline: the authors reported the percentage change as significant and the absolute change as just short of significance, in a study they noted was too small for the absolute measure. The main planned test of fatigue resistance was negative, though two reanalyses done afterwards were suggestive. By day 7 the two groups were no longer different [6].
What is clearly real: elamipretide can change mitochondrial energy measurements in humans, and it holds a disease-specific FDA approval. What is not established: a predictable “energy boost” for ordinary users. How energetic you feel depends on many things, and the largest placebo-controlled study found no reliable advantage on tiredness. A measurable rise in cell energy output does not automatically become better endurance, less tiredness or a noticeable lift.
The mitochondrial repair story
Does SS-31 really “repair” damaged mitochondria?
The word repair has some basis. Elamipretide binds cardiolipin, a fat that helps organise the inner wall of the mitochondria and the protein machinery that makes energy there. In systems that are already malfunctioning, that interaction can improve how well the mitochondria work [1,6,13,14].
- Cardiolipin matters. It helps hold the inner membrane and the energy-making machinery in the right arrangement.
- SS-31 binds there. Elamipretide gathers in the parts of the membrane that are rich in cardiolipin.
- Function can improve. Human and lab studies show better energy output in some situations.
| Framing | Statement |
|---|---|
| Fair shorthand | “SS-31 can steady mitochondrial membrane function and improve energy output in some malfunctioning settings.” |
| Taking it too literally | “SS-31 rebuilds broken mitochondria, repairs mitochondrial DNA, or permanently fixes the structure.” |
An important human clue: in the older-adult study, the energy-production advantage showed up straight after treatment, and by day 7 it had gone [6]. SS-31 can improve function without permanently rebuilding anything. “Steadying how it works” is more accurate than picturing a broken machine that gets fixed once and stays fixed.
Would you know if your mitochondria needed repair?
Usually not. Tiredness, brain fog, poor recovery, struggling with exercise and simply getting older can all happen alongside mitochondrial problems, but none of them points to one cause. Poor sleep, eating too little, low iron, thyroid problems, medications, illness, low mood and plain fitness level can all produce the same feelings [16,17].
One SS-31 study makes this point. Of 120 older adults aged 60 to 85 who were screened, 47 were turned away because their mitochondria were working too well to qualify, and a further 34 were excluded on clinical grounds. Only 39 were randomised, after testing showed low function. Being older did not automatically mean they needed treatment [6].
A real mitochondrial assessment involves:
- The clinical picture: doctors look for a pattern of symptoms across multiple organs, not tiredness on its own.
- Genetic testing: testing mitochondrial DNA and related genes is central when an inherited mitochondrial disorder is suspected.
- Supporting tests: blood tests such as lactate and pyruvate can support the picture. Scans, exercise testing and sometimes a tissue sample are used when the clinical picture calls for it.
There is no routine test that tells an ordinary person “your mitochondria are 40% damaged,” and symptoms alone cannot tell you that either.
Does feeling better or worse prove anything?
No. A common logic error is using your reaction to the drug as proof of the problem that supposedly justified taking it.
| Outcome | What gets claimed | What it can actually mean |
|---|---|---|
| You feel better | “The repair worked,” so your mitochondria must have been damaged. | A real drug effect is possible. So is a placebo effect, a change in sleep or activity, something else you were taking, ordinary day-to-day variation, or a benefit that says nothing about what caused the symptom. In the older-adult study, the placebo group's cell energy output also rose measurably right after infusion. |
| You feel nothing | “Your mitochondria were probably healthy already.” | It could mean no meaningful effect, that the thing being measured was never relevant to you, person-to-person variation, or a difference in the product itself. There is no validated “SS-31 response test.” |
| You feel worse | “Repair is happening, and it takes energy,” or “deep mitochondrial cleanup.” | It means the person feels worse. The cause could be the drug, the underlying condition, another treatment, sleep, food, an illness or something else. Getting worse is not evidence that a treatment is working. |
Every possible outcome gets used to confirm the same theory, and a claim that cannot fail is neither a biomarker nor a clinical test. Human trials tracked energy production, walking distance, tiredness, muscle strength and similar outcomes. None of them describes an expected early “repair crash” or a tiredness phase that proves rebuilding is happening. A response to treatment can show that something changed, but it usually cannot tell you what was wrong beforehand.
“Fix the engine before you add fuel”: does the SS-31 + NAD+ logic hold up?
A widespread analogy describes the body as a machine, mitochondria as the engine, NAD+ as the fuel, SS-31 as the mechanic and MOTS-c as the turbo. The conclusion follows neatly: if the machinery is damaged, NAD+ or MOTS-c will not work well until SS-31 fixes it first. The analogy borrows several true statements. Mitochondria do make most of the body's energy, cardiolipin does help organise the inner membrane, SS-31 does target that membrane, NAD+ is essential to energy metabolism, and MOTS-c does affect metabolic signalling [6,13,18].
| Where the analogy breaks | Why |
|---|---|
| NAD+ is not literally fuel | The chemical energy comes from food. NAD+ is mainly a helper molecule that shuttles electrons, moving that energy through metabolism. Calling it fuel makes it sound like something you can top up like a petrol tank [18]. |
| The “broken engine” is usually assumed | Tiredness or brain fog does not establish cardiolipin damage, or any mitochondrial defect that would need SS-31 first [16,17]. |
| The sequence has never been tested | No controlled human trial has shown that taking SS-31 first makes NAD+ or MOTS-c work better than taking them without a “repair phase.” |
| The repair is not proven permanent | In the older-adult study, the energy advantage faded rather than sticking as a one-time fix [6]. |
The machine-and-fuel analogy explains the theory. It does not prove the protocol.
Heart, kidneys, brain and aging
Mitochondria are found in almost every tissue, so a mitochondrial drug can be made to sound relevant to almost every organ. Results in specific conditions carry more weight than the mechanism on its own.
| Claim | Verdict | What the evidence shows |
|---|---|---|
| Heart “repair” | Not established | A 71-person heart-failure trial did not improve its main measures of heart structure and pumping, and the heart-attack trial did not reduce the amount of damaged muscle [10,11]. |
| Kidney “repair” | Preliminary only | A 14-person pilot in people having a narrowed kidney artery stented produced encouraging blood-flow signals. Fourteen people is not enough to establish SS-31 as a kidney-repair therapy [12]. |
| Brain fog and thinking | Not established | No controlled human trial has been identified showing that SS-31 reliably improves ordinary brain fog or mental sharpness in healthy people. |
| Anti-aging | Not established | The older-adult study was a short experiment measuring cell energy output. It did not study lifespan, dementia prevention or reversing biological age [6]. |
The anti-aging claim sounds believable because two parts are true: mitochondrial function can decline with age (though not for everyone and not evenly), and SS-31 affects underperforming systems, with strong animal data and a direct human signal on cell energy output. The jump to “therefore it reverses aging” is where the reasoning breaks: no human trial has measured lifespan or years of healthy life on this drug. A pathway being involved in a disease or in aging does not prove that changing that pathway will repair the organ, reverse the disease or add healthy years.
Safety and product reality
The 2025 Forzinity approval gives far better safety and absorption information than older peptide write-ups could. It also makes one distinction clear: an approved, ready-made medicine is not the same thing as a freeze-dried research vial [1,3].
| Issue | What is established |
|---|---|
| Injection-site reactions | Very common in the Barth programme. Redness, pain, hardening of the skin and itching were all frequent [1,2]. |
| Allergic reactions | Serious allergic reactions can happen, and they are listed in the official FDA label [1]. |
| White blood cell changes | Some patients showed raised counts of eosinophils, a type of white blood cell, during longer treatment [1]. |
| Cleared by the kidneys | The drug and its inactive breakdown products leave the body mainly in urine. Poor kidney function raises blood levels, which is why the adult dose is reduced in that situation [1,3]. |
| It does not build up | At 40 mg a day it clears the blood within a few hours and barely accumulates. Trials still used once-daily dosing [3]. |
An approved medicine compared with a research vial
- Forzinity, the approved product: a sterile, ready-to-use 80 mg/mL prescription solution. Its inactive ingredients, storage rules and handling instructions were all reviewed as part of the approval.
- A vial labelled “SS-31”: freeze-dried powder mixed up by a research vendor. Identity, strength, inactive ingredients, sterility and shelf stability fall outside that reviewed evidence package.
The approved product's storage and handling instructions cannot simply be transferred to research vials, and a vial labelled “SS-31” from outside that system cannot be assumed to be the same thing.
Evidence summary
| Claim | Verdict | Basis |
|---|---|---|
| “SS-31 repairs mitochondria” | Partly true, too literal | Real cardiolipin-targeted biology and real improvement in function. Permanent rebuilding is not established. |
| Tiredness or brain fog means damaged mitochondria | Not a diagnosis | Those symptoms are far too general; a real assessment is much more involved [16,17]. |
| Feeling better proves damage was repaired | Not established | How you respond to SS-31 is not a validated diagnostic test. |
| Feeling worse means “deep repair” | No human evidence | No trial describes a repair crash or cleanup phase. |
| SS-31 must come before NAD+ or MOTS-c | Never tested | The machine-and-fuel analogy is reasoning about mechanism, not a tested human sequence. |
| SS-31 can change cell energy output | Borderline human signal | Energy output improved right away in selected older adults with measurably low function, in a small study with a borderline result [6]. |
| SS-31 reliably improves tiredness or endurance | Mixed to negative | Small hints were not confirmed in the 218-person MMPOWER-3 trial [8,9]. |
| FDA approval proves general mitochondrial repair | No | The approval is for muscle strength in Barth syndrome at 30 kg and above, under accelerated approval [1,2]. |
| 4 to 8 weeks, then “repair complete” | Unvalidated | No human milestone supports this cycle. |
| 5-on / 2-off, morning or pre-workout timing | Ruled out | The drug's absorption and clearance give no basis for weekend breaks or workout timing [1,3]. |
| A “sensible” wellness dose | Does not exist | Only 4 mg and 40 mg have been given by injection in human trials, both in trials that missed their primary endpoints. Nothing in between has been studied [1,9,10]. |
| Heart, kidney or brain repair | Not broadly established | Human results are condition-specific and mixed; the kidney evidence is preliminary [10-12]. |
| Anti-aging or longer life | Not established | No human trial has measured lifespan or years of healthy life [6]. |
Conclusion
What is real: SS-31 is a genuine cardiolipin-targeted mitochondrial drug, with a narrow FDA-approved use, real measurable activity in humans and years of clinical development behind it.
What gets added online: a home diagnosis of “broken mitochondria,” guaranteed energy, a deep-repair crash, mandatory SS-31-first sequencing, fixed repair cycles, and broad anti-aging or organ-repair claims.
The online repair story starts with real biology and then stretches it into diagnoses and protocol rules the human trials have never established. SS-31 does affect mitochondria. The useful question is whether a particular person has a mitochondrial problem that this drug has been shown to improve.
Sources
- U.S. FDA. Forzinity (elamipretide) Prescribing Information. Initial U.S. approval 2025. Indication, 40 mg once-daily SC dose, renal adjustment, safety, formulation and administration.
- U.S. FDA. Drug Trials Snapshot: Forzinity. Pivotal 12-person Barth syndrome trial, original walk and fatigue endpoints, muscle-strength data and adverse reactions.
- U.S. FDA. Integrated Review, NDA 215244 (2025). Pharmacology, pharmacokinetics, evidence review and accelerated-approval reasoning.
- Thompson WR, et al. Genetics in Medicine. 2021;23:471-478. Randomized crossover trial and open-label extension in Barth syndrome. PMID 33077895.
- Thompson WR, et al. Genetics in Medicine. 2024;26(7):101138. 168-week open-label extension in Barth syndrome. PMID 38602181.
- Roshanravan B, et al. PLoS One. 2021;16:e0253849. Randomized older-adult study: 120 screened, 39 randomized for low mitochondrial function; acute ATPmax response and fatigue-resistance testing. PMID 34264994.
- Karaa A, et al. Neurology. 2018;90:e1212-e1221. MMPOWER randomized dose-escalation trial in primary mitochondrial myopathy. PMID 29500292.
- Karaa A, et al. J Cachexia Sarcopenia Muscle. 2020;11:909-918. MMPOWER-2, 40 mg SC daily crossover trial. PMID 32096613.
- Karaa A, et al. Neurology. 2023;101:e238-e252. MMPOWER-3, 218-person Phase 3 trial; walking and fatigue primary endpoints not met. PMID 37268435.
- Butler J, et al. Journal of Cardiac Failure. 2020;26:429-437. PROGRESS-HF: 4 or 40 mg SC daily for 28 days; no significant improvement in primary LV endpoints. PMID 32068002.
- Gibson CM, et al. European Heart Journal. 2016;37:1296-1303. EMBRACE STEMI: IV MTP-131 did not reduce infarct size or improve prespecified outcomes. PMID 26586786.
- Saad A, et al. Circulation: Cardiovascular Interventions. 2017;10:e005487. Small randomized renal-artery-stenosis pilot during stenting. PMID 28916603.
- Tung C, et al. International Journal of Molecular Sciences. 2025;26:944. Review of elamipretide, cardiolipin mechanism and clinical development. PMID 39940712.
- Chavez JD, et al. PNAS. 2020;117:15363-15373. SS-31 mitochondrial protein-interaction landscape. PMID 32554501.
- U.S. FDA. “FDA Grants Accelerated Approval to First Treatment for Barth Syndrome.” 19 September 2025.
- Chinnery PF. Primary Mitochondrial Disorders Overview. GeneReviews. Diagnostic approach, metabolic tests, imaging and exercise testing, and genetic testing.
- Parikh S, et al. Genet Med. 2015/2016. Diagnosis and management of mitochondrial disease: Mitochondrial Medicine Society consensus statement.
- Molecular Biology of the Cell / NCBI Bookshelf. NAD+ and NADH as electron-carrying redox coenzymes in cellular metabolism.
- U.S. FDA Accelerated Approval Program. Ongoing Forzinity postmarketing requirement for a randomized confirmatory trial.
Community sources
These record what people are being told online. They are not evidence that the claims are true.
- PeptPath, “Repair First, Optimize Second: The Smart Way to Stack SS-31, MOTS-c & NAD+” (June 26, 2026). Repair-first sequencing.
- Reddit / r/PeptideGuide, “Running MOTS-c and SS-31 at the same time” (Apr. 8, 2026). Claim that a strong SS-31 response means the mitochondria were damaged and are now repaired.
- Alpha Peptide Research Labs, SS-31 page. Car analogy: NAD+ as fuel, MOTS-c as performance upgrade, SS-31 as the mechanic.
- Reddit / r/Biohackers, “SS-31 exhaustion, fatigue even more brain fog” (Mar. 3, 2026). Worsening fatigue interpreted as the peptide “repairing” damage.
- Reddit / r/Biohacking, “Low energy on SS-31” (Aug. 19, 2026). The “deep mitochondrial cleanup” explanation for early fatigue.
- Reddit / r/Biohacking, “SS-21 Questions” (June 19, 2026). SS-31 as mechanic, NAD as fuel, MOTS-c as turbo.
- Reddit / r/Biohacking, “MOTS-c + NAD+ without SS-31” (Apr. 19, 2026). Advice not to run NAD+ or MOTS-c without SS-31 repair first.
- Peptide Supermarket, “Why Most People Use MOTS-C Wrong” (2026). Commercial repair-first cycle: SS-31 + NAD+ first, then MOTS-c, followed by time off.
- Peptide Dosing Protocols, SS-31 protocol (2026). Lists 5 mg/day as a common anecdotal cluster, with 1 mg/day low-support and 10 to 20 mg/day higher community ranges.
- The Peptide Catalog, SS-31 dosing guide (2026). A 500 mcg daily, 5-on/2-off, 8-week community protocol, contrasted with much higher clinical doses.
- Advance Peptides Canada, SS-31 dosing protocol (2026). 500 mcg daily initially, then 1 to 2 mg/day, 5-on/2-off; maximum 5 mg in that guide.
- PeptideDosages.com, SS-31 protocol (2026). Lists 5 to 10 mg SC daily as typical, with higher 15 to 20 mg/day protocols.